# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amge...
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clini...
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vac...
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human...
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safe...
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions.